(Q52167880)

26 April 2018

title

Effects of cholinesterase inhibitors on a two-component chained schedule performance in rats. (English)

1 reference

26 April 2018

author name string

Liu WF

series ordinal

1

1 reference

26 April 2018

publication date

1 May 2000

1 reference

26 April 2018

Neurotoxicology and Teratology

published in

1 reference

26 April 2018

volume

22

1 reference

26 April 2018

issue

3

1 reference

26 April 2018

page(s)

389-396

1 reference

26 April 2018

The use of carbamates and atropine in the protection of animals against poisoning by 1,2,2-trimethylpropyl methylphosphonofluoridate

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

A long-lasting cholinesterase inhibitor affecting neural and behavioral processes.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Reversibility of the inhibition of acetylcholinesterase by tacrine

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Comparison of DuP 996, with physostigmine, THA and 3,4-DAP on hypoxia-induced amnesia in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Tacrine: A pharmacological review

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Effectiveness of 1,2,3,4-tetrahydro-9-aminoacridine (THA) as a pretreatment drug for protection of mice from acute diisopropylfluorophosphate (DFP) intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Hemicholinium-3 impairs spatial learning and the deficit is reversed by cholinomimetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Toxicity of anticholinesterases: interactions of pyridostigmine and physostigmine with soman

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Acetylcholinesterase inhibition and anti-soman efficacy of homologs of physostigmine

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Low dose tetrahydroaminoacridine (THA) improves cognitive function but does not affect brain acetylcholine in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Treatment of poisoning by soman.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Relationship between reversible acetylcholinesterase inhibition and efficacy against soman lethality.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Cholinolytic antagonism to the disruptive effects of oral low doses of pyridostigmine on simple discrimination performance in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Acute effects of oral low doses of pyridostigmine on simple visual discrimination and unconditioned consummatory acts in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Effects of antimuscarinic antiparkinsonian drugs on brightness discrimination performance in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Differential effects of physostigmine and pilocarpine on the spatial memory deficits produced by two septo-hippocampal deafferentations in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Efficacy of physostigmine as a pretreatment for organophosphate poisoning

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Effect of age and strain on working memory in mice as measured by win-shift paradigm.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

The effects of THA on medial septal lesion-induced memory defects.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

In vivo dose response relationship between physostigmine and cholinesterase activity in RBC and tissues of rats

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Kinetics of cholinesterase inhibition by eptastigmine in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Differential effects of physostigmine and 1,2,3,4-tetrahydro-9-aminoacridine on the beta-adrenoceptor transduction system

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus basalis

1 reference

https://api.crossref.org/works/10.1016%2FS0892-0362%2899%2900086-0

7 January 2021

10.1016/S0892-0362(99)00086-0

Identifiers

DOI

1 reference

26 April 2018

1 reference

26 April 2018